DEMYELINATING DISEASES: Edited by Hans-Peter HartungCurrent therapeutic landscape in multiple sclerosis: an evolving treatment paradigmCree, Bruce A.C.a; Mares, Janb; Hartung, Hans-Peterc Author Information aDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA bDepartment of Neurology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic cDepartment of Neurology, Medical Faculty and Center for Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Correspondence to Bruce A.C. Cree, MD, PhD, MAS, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA. Tel: +1 415 353 2069; fax: +1 415 353 2633; e-mail: [email protected] Current Opinion in Neurology: June 2019 - Volume 32 - Issue 3 - p 365-377 doi: 10.1097/WCO.0000000000000700 Buy Erratum Metrics Abstract Purpose of review To critically assess the current landscape of disease-modifying agents for multiple sclerosis (MS). Treatment algorithms will be discussed and studies for new agents in late development or recently approved are analyzed in terms of their impact on current treatment strategies. Recent findings A real-world study from Wales suggests that early initiation of highly effective therapy may provide more benefit that an escalation approach in relapsing MS. A study from the MSBase dataset found evidence that early treatment with highly effective therapies decreased the risk of developing secondary progressive MS. Ocrelizumab is highly efficacious in relapsing MS and in a group of patients with primary progressive MS. Another CD20 directed mAb, ofatumumab, is in phase 3. A large study examining extended interval dosing of natalizumab in an attempt to decrease the risk of developing progressive multifocal leukoencephalopathy is underway. Cladribine and alemtuzumab may work by immune reconstitution. Siponimod was recently approved by United States Federal Drug Administration for relapsing MS and active secondary progressive MS. Other S1P receptor modulators are being studied in phase 3 trials for relapsing MS. Cladribine received FDA approval as treatment for relapsing and active secondary progressive MS. Autologous hematopoetic stem-cell transplantation may be an option for treatment-refractory MS. Summary Development of disease-modifying agents in MS continues to be successful. Treatment algorithms need to take new developments into account. Erratum Figure 7 in the article, ‘Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm’ which published in the June 2019 issue of Current Opinion in Neurology, included an error . Authors confirmed Ozanimod had no impact on EDSS in either SUNBEAM or RADIANCE. The correct text from the figure should read: “A significant reduction in risk of 3m-CDP vs. IFN β-1a was not reached in the pooled analysis of SUNBEAM and RADIANCE studies.” 5+ images Current Opinion in Neurology. 32(5):782, October 2019. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.